AstraZeneca made $10 billion offer for obesity drugmaker Rhythm, sources say
AstraZeneca (AZN) reportedly offered $10 billion, or up to $134 per share, to acquire Rhythm Pharmaceuticals (RYT), according to sources. Rhythm's shares rose 28% to $110.68, valuing it at $7.64 billion. The deal would expand AZN's rare-disease portfolio via its Alexion unit. Rhythm's Imcivree is approved for a rare obesity condition. AZN seeks growth amid recent setbacks.
How this was made
The 30-second read
Why it matters
The acquisition could accelerate AstraZeneca's entry into the fast‑growing obesity market while providing Rhythm shareholders a premium exit.
Market read
The deal is a material M&A event with immediate price impact on both stocks and broader biotech M&A sentiment.
What to watch
Regulatory scrutiny of large pharma acquisitions and potential antitrust hurdles could delay or block the transaction.
Background
AstraZeneca seeks to expand its rare‑disease franchise by acquiring Rhythm, which holds the obesity drug Imcivree and other rare‑metabolic therapies.
Ticker impact
AstraZeneca announced a non‑binding $10 billion offer to acquire Rhythm Pharmaceuticals, a material M&A move.
likely modest downside as market prices in acquisition cost and integration risk
Large‑cap pharma deals typically cause short‑term share pressure while investors assess valuation and debt impact.
Market effects
Strengthens consolidation trend in obesity and rare‑disease therapeutics, may spur M&A activity in biotech.
European and US pharma markets watch for valuation benchmarks.
Highlights growing investor focus on high‑growth specialty medicine segments.
Counterpoint
The deal could overpay for Rhythm's niche portfolio, risking dilution for AstraZeneca shareholders.
Key entities
- CompanyAstraZeneca
Global pharmaceutical firm pursuing growth through acquisitions.
- CompanyRhythm Pharmaceuticals
Developer of obesity and rare‑disease therapies, target of the $10 billion offer.
